Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07470840
PHASE2

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Sponsor: Fujian Cancer Hospital

View on ClinicalTrials.gov

Summary

To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.

Official title: A Phase II Multicenter Study of Stereotactic Body Radiation Therapy (SBRT) Combined With Anlotinib and Bimepolizumab in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

27

Start Date

2027-02-01

Completion Date

2029-06-01

Last Updated

2026-03-24

Healthy Volunteers

No

Interventions

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

Dose fractionation: 39-48Gy/3f or 40-50Gy/5f, alternative 20-50Gy/5f if OAR dose-limited. Dose adjusted per radiation toxicities during treatment.

DRUG

Anlotinib

Oral anti-angiogenic agent, 12 mg qd fasting, 21d/cycle (2w on/1w off)

DRUG

Bemarituzumab

Intravenous PD-1 inhibitor, 1200 mg q3w, 60min infusion

Locations (1)

Fujian Cancer Hospital

Fuzhou, Fujian, China